Company intelligence
ImpediMed
About ImpediMed
ImpediMed is a global medical technology company that designs and manufactures bioimpedance spectroscopy (BIS) devices, providing clinicians with real-time insights for personalized patient care. The company's SOZO® Digital Health Platform and L-Dex® are the first and only FDA-cleared BIS technology that noninvasively measures fluid status and tissue composition for both healthy and unhealthy populations and the assessment and management of secondary lymphedema, with a focus on breast cancer-related lymphedema (BCRL). The platform also supports structured cancer survivorship programs and medical weight management, including patients on GLP-1 therapies, by providing real-time, whole-body insights. Trusted by healthcare organizations and research institutions worldwide, ImpediMed is redefining how clinicians monitor and manage body fluid and tissue status across diverse care pathways.
Verified activity
Signals from ImpediMed
3 published signals
Presence & Recognition
ImpediMed is supporting Living Beyond Breast Cancer's upcoming CE webinar for healthcare providers covering weight management, GLP-1s, and shared decision-making.
Reported by ImpediMed
Legal & Regulatory
ImpediMed announced that the SOZO® Digital Health Platform is now FDA-cleared for sarcopenia risk assessment, serving as the only FDA-cleared bioimpedance spectroscopy (BIS) solution for clinical assessment of sarcopenia risk in oncology care.
Reported by ImpediMed
Products & Services
ImpediMed announced the SOZO Digital Health Platform with L-Dex supports early detection as part of structured lymphedema surveillance in line with NCCN guidelines and NAPBC standards.
Reported by ImpediMed